Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Review

Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management

Flavia V Castelino1* and John Varga2

Author affiliations

1 Division of Rheumatology, Bulfinch-165, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Boston, MA 02114, USA

2 Division of Rheumatology, Northwestern University Feinberg School of Medicine, McGaw 2300, 240 East Huron Street, Chicago IL 60611, USA

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2010, 12:213  doi:10.1186/ar3097

Published: 23 August 2010

Abstract

Interstitial lung disease (ILD) is a challenging clinical entity associated with multiple connective tissue diseases, and is a significant cause of morbidity and mortality. Effective therapies for connective tissue disease-associated interstitial lung disease (CTD-ILD) are still lacking. Multidisciplinary clinics dedicated to the early diagnosis and improved management of patients with CTD-ILD are now being established. There is rapid progress in understanding and identifying the effector cells, the proinflammatory and profibrotic mediators, and the pathways involved in the pathogenesis of CTD-ILD. Serum biomarkers may provide new insights as risk factors for pulmonary fibrosis and as measures of disease progression. Despite these recent advances, the management of patients with CTD-ILD remains suboptimal. Further studies are therefore urgently needed to better understand these conditions, and to develop effective therapeutic interventions.